We assessed adherence to r-hGH treatment in children with growth disorders over 48 months using a connected monitoring device (easypodTM), which automatically transmits adherence data via an online portal (easypodTM connect); both sit within an adherence decision support system (ADSS). Here, GH1 is linked to hereditary endocrine growth disease.